AIN
Enabling Exosome Therapy

Enabling Exosome Therapy

location_on York & Humb ,  United Kingdom

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

Mesenbio is developing new arthritis medicines using exosomes – tiny natural messengers from stem cells that calm inflammation and repair tissue. Our unique platform also provides pharma companies with consistent tools for drug discovery.

Highlights

  • Proprietary stem cell platform proven for consistent, scalable exosomes
  • Candidate MEV-N01 shows efficacy in preclinical rheumatoid arthritis models
  • £1.4M raised (Innovate UK + private)
  • Revenue potential from pharma licensing of FT-01 exosome platform
  • Blockbuster potential for MEV-N01 as a first-in-class arthritis therapy

Overview

Target CA$ 750,000
Minimum CA$ 20,000
Investment Raised CA$ 0
Previous Rounds CA$ 2,800,000
Stage Pre-Startup/R&D
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects